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Abstract
Background: The rationale for use of drugs during pregnancy requires a careful assessment as in addition to the mother,
the health and life of her unborn child is also at stake. Information on the use of drugs during pregnancy is not available
in Pakistan. The aim of this study was to evaluate the patterns of drug prescriptions to pregnant women in tertiary care
hospitals of Pakistan.
Methods: This was a cross-sectional study conducted at five tertiary care hospitals of Pakistan. Copies of outpatient
medicinal prescriptions given to pregnant patients attending the antenatal clinics were collected. The drugs were
classified according to the pharmacological class and their teratogenic potential.
Results: All the pregnant women attending the antenatal clinics received a prescription containing at least one drug. A
total of 3769 distinct prescriptions given to different women were collected. Majority of the women who received the
prescriptions belonged to third trimester (55.4%) followed by second (33.6%) and first trimester (11.0%). On an average,
each prescription contained 1.66 ± 0.14 drugs. The obstetricians at Civil Hospital, Karachi and Chandka Medical College
Hospital, Larkana showed a tendency of prescribing lesser number of drugs compared to those in other hospitals. Anti-
anemic drugs including iron preparations and vitamin and mineral supplements (79.4%) were the most frequently
prescribed drugs followed by analgesics (6.2%) and anti-bacterials (2.2%). 739 women (19.6%) received prescriptions
containing drugs other than vitamin or mineral supplements. Only 1275 (21.6%) of all the prescribed drugs (n = 6100)
were outside this vitamin/mineral supplement class. Out of these 1275 drugs, 29 (2.3%) drugs were prescribed which are
considered to be teratogenic. Misoprostol was the most frequently prescribed (n = 6) among the teratogenic drugs
followed by carbimazole (n = 5) and methotrexate (n = 5). Twenty nine pregnant women (0.8% of all the women studied)
were prescribed these teratogenic drugs.
Conclusion: Less than one percent of the pregnant women attending tertiary care hospitals in Pakistan are prescribed
teratogenic drugs. The prescribing practices of Pakistani physicians are similar to those in western countries.
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Background
Careful consideration of the benefit to the mother and the
risk to the fetus is required while prescribing drugs during
pregnancy. Reducing medication errors and improving
patient safety are the important areas of discussion [1].
The use of drugs during pregnancy calls for special atten-
tion because in this case in addition to the mother, the
health and life of her unborn child is also at stake. The
drugs given to pregnant mothers for therapeutic purposes
may cause serious structural and functional adverse effects
in the developing child [2]. Since it is very difficult to
determine the effects on the fetus before marketing new
drugs due to obvious ethical reasons, most drugs are not
recommended to be used during pregnancy [3].
Since there are numerous gaps in knowledge about dele-
terious consequences for the fetus, prescription drug use
by pregnant women should be viewed as a public health
issue [4]. Pharmacoepidemiological studies can measure
the extent of prescription and teratogenic drug use in preg-
nant women. The studies conducted in developed coun-
tries where drug-prescribing practices are considered to be
superior, have identified need for interventional measures
aimed at rational prescription during the prenatal period
[5,6]. Similar type of pharmacoepidemiological studies
auditing the use of drugs during pregnancy have not been
conducted in Pakistan. Hence the aim of this study was to
examine the patterns of drug prescription during preg-
nancy in the tertiary care hospitals of Pakistan. With this
information, we intend to provide feedback and recom-
mendations for the health care providers.
Methods
This was a cross-sectional study conducted at five tertiary
care hospitals of Pakistan i.e Aga Khan university Hospital
(AKUH), Karachi, Civil Hospital (CH), Karachi; Nawab-
shah Medical College Hospital (NMCH), Nawabshah;
Chandka Medical College Hospital (CMCH), Larkana and
Bolan Medical College Hospital (BMCH), Quetta. The
sampling units were carefully selected so as to get the data
that can maximally represent the prescribing trends in
Pakistan. Briefly, the sampling units were a mix of public
sector (CH, NMCH, BMCH and CMCH) and private sec-
tor (AKUH). It was also a mix of metropolitan (AKUH and
CH) and smaller town hospitals (CMCH, NMCH and
BMCH). Ethical clearance was obtained from the Ethical
Review Committee of the Aga Khan University, Karachi.
In addition to that a written clearance was obtained form
the Heads of the sampling units for obtaining the data
from their respective Hospitals. Copies of outpatient drug
prescriptions given to pregnant patients attending the
antenatal clinics of CH, NMCH, CMCH, and BMCH were
collected by the data collectors from January 1 to April 30,
2007. Before making copies of the prescription, verbal
consent was obtained from the women whom prescrip-
tions were issued. Since the AKUH maintains a record of
all the patients attending the clinics, data was collected
from the medical records of the pregnant women attend-
ing the antenatal clinics during the above-mentioned
period. In order to prevent bias, the prescribers were kept
unaware about the collection of prescriptions. The pre-
scriptions given to women on repeat visits were not
included, so effectively all the prescriptions analyzed in
this study represent different women.
Data was recorded on a structured questionnaire that con-
tained information on the demography of patients, brand
names of the drugs prescribed and number of drugs writ-
ten in each prescription.
All the completed questionnaires were pooled together.
The generic names and then the pharmacological class of
each drug prescribed to pregnant women were identified
by a drug data base published every year in Pakistan [7].
The collected data was entered and analyzed using statis-
tical software SPSS (version 15.0). One way ANOVA was
used to compare the number of drugs prescribed in each
sampling unit.
Results
All the pregnant women attending the antenatal clinics of
all five sampling units received a prescription containing
at least one drug during their visits. A total of 3769 pre-
scriptions issued to the same number of women were col-
lected. The number of prescriptions collected from all five
centers was more or less in the similar range. The maxi-
mum (879) and minimum (601) number of prescriptions
were collected from CMCH and CH, respectively. The
mean age of the women under study was 28.3 ± 2.4 years.
The distribution of gestational age of the women in all
sampling units whose prescriptions were collected is pre-
sented in Table 1. As evident from Table 1, the maximum
number of prescriptions was collected from women in
their third trimester of pregnancy (55.4%) followed by
second (33.6%) and first trimester (11.0%).
While analyzing the number of drugs prescribed to preg-
nant women, it was found out that on the average, each
prescription contained 1.66 ± 0.14 drugs. Interestingly,
the obstetricians at CH and the CMCH had the tendency
of prescribing lesser number of drugs compared to AKUH,
BMCH and NMCH, as shown in Table 1.
The pharmacological classes of drugs prescribed to preg-
nant women were also analyzed. As shown in Table 2,
anti-anemic drugs including iron preparations and vita-
min and mineral supplements (79.4%) were the most fre-
quently prescribed drugs followed by analgesics (6.2%).BMC Pregnancy and Childbirth 2008, 8:24 http://www.biomedcentral.com/1471-2393/8/24
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Further analysis was done to determine the extent of pre-
scription of potentially teratogenic dugs. In this analysis,
we did not include the vitamin and mineral supplements
prescribed to pregnant women. Out of 3769 women
included in this study, 739 (19.6%) received prescriptions
containing drugs other than vitamin or mineral supple-
ments. Only 1275 (21.6%) of all the prescribed drugs (n
= 6100) were outside this vitamin/mineral supplement
class. Out of these 1275 drugs, 29 (2.3%) drugs were pre-
scribed which are considered to have teratogenic poten-
tial. Twenty nine pregnant women (0.8% of all the
women studied) were prescribed these teratogenic drugs.
Table 3 depicts the distribution of teratogenic drugs pre-
scribed in the present study. Misoprostol was the most fre-
quently prescribed (n = 6) among the teratogenic drugs
followed by carbimazole (n = 5) and methotrexate (n =
5).
Discussion
Although a number of similar studies have been con-
ducted in the western countries, this is the first one con-
ducted in Pakistan which has determined the prescribing
attitudes of antenatal care providers in tertiary care hospi-
tals. Furthermore, this study has determined the extent of
Table 1: Trimester-wise break up of patients attending the antenatal clinics, whose prescriptions were collected.
Trimester of Drug Prescription Sampling Unit Total
AKUH CH CMCH BMCH NMCH
n (%) n (%) n (%) n (%) n (%) n (%)
First trimester 16 (2.3) 29 (4.8) 128 (14.6) 132 (17.4) 105 (13.3) 410 (11.0)
Second trimester 203 (29.0) 158 (26.4) 287 (32.8) 331 (43.6) 271 (34.3) 1250 (33.6)
Third trimester 482 (68.8) 412 (68.8) 460 (52.6) 296 (39.0) 415 (52.5) 2065 (55.4)
Did not specify* 10 2 4 20 8 44
Total 711 (18.9) 601 (15.9) 879 (23.3) 779 (20.7) 799 (21.2) 3769 (100.0)
Mean ± SEM of number of drugs prescribed 1.84 ± 0.039 1.35 ± 0.023 1.39 ± 0.020 1.78 ± 0.027 1.92 ± 0.040 1.66 ± 0.014**
Range 1 – 10 1 – 5 1 – 4 1 – 6 1 – 8 1 – 10
*These observations are not included in the percentage distribution of total number of patients by hospitals.
** p-value < 0.001 (using One Way ANOVA) i.e. a significant association was observed between number of drugs prescribed and hospitals. CH and 
CMCH are prescribing lesser number of drugs as compared to other hospitals.
Table 2: Distribution of Drug Classes prescribed to pregnant women.
Pharmacological Class Gestational age (Trimester)
First n Second n Third n Total n
(%) (%) (%) (%)
Anti-anemic/vitamin and mineral supplements 491 (75.5) 1577 (78.8) 2775 (80.5) 4843 (79.4)
Analgesics (including opioids) 50 (7.7) 132 (6.6) 200 (5.8) 382 (6.2)
Anti-platelets/anti-coagulants 11 (1.7) 21 (1.1) 23 (0.7) 55 (0.9)
Estrogens/anti-estrogen 1 (0.6) 4 (0.4) 10 (0.9) 15 (0.2)
Progesterones 5 (0.8) 30 (1.5) 30 (0.9) 65 (1.1)
Corticosteroids (oral, injectable, inhalational and topical) 5 (0.8) 40 (2.0) 71 (2.1) 116 (1.9)
Antacids 6 (0.9) 32 (1.6) 34 (1.0) 72 (1.2)
Anti-histamines 8 (1.2) 10 (0.5) 18 (0.5) 36 (0.6)
Anti-emetics 31 (4.8) 30 (1.5) 32 (0.9) 93 (1.5)
Anti-bacterial (oral and topical) 10 (1.5) 32 (1.6) 91 (2.6) 133 (2.2)
Anti-fungal (oral and topical) 0 (0.0) 2 (0.1) 21 (0.6) 23 (0.4)
Anti-helminthic 2 (0.3) 3 (0.1) 13 (0.4) 18 (0.3)
Anti-asthmatic (oral and inhalational) 5 (0.8) 13 (0.6) 17 (0.5) 35 (0.6)
Anti-cholinergics 12 (1.8) 49 (2.4) 73 (2.1) 134 (2.2)
CNS drugs including anti- epileptics 4 (0.6) 9 (0.4) 13 (0.4) 26 (0.4)
Miscellaneous 9 (1.4) 18 (0.9) 27 (0.8) 54 (0.9)
Total 650 (100.0) 2002 (100.0) 3448 (100.0) 6100 (100.0)BMC Pregnancy and Childbirth 2008, 8:24 http://www.biomedcentral.com/1471-2393/8/24
Page 4 of 5
(page number not for citation purposes)
prescription of drugs which are considered teratogenic for
the fetus. To the best of our knowledge, there is only one
other study in South Asia that has examined the prescrib-
ing behavior of physicians in pregnant women in India,
focusing on the pharmacological class of the drugs and
their safety profile [8]. The strength of the present study is
that the determination of exposure of drugs was based on
physical prescriptions rather than on recall, which may
lead to bias or underascertainment [9].
Based on limited reported effects in humans and more
extensive studies with animals, different classification sys-
tems have been made. Swedish system was the first to be
implemented in 1978 [10]. Later on, US Food and Drug
Administration (FDA) classified the drugs into categories
based on the risk of induction of fetal toxicity. Many pre-
vious studies have used these risk classification systems as
the tools to evaluate the prescribing behaviors of the phy-
sicians to pregnant women [8,11-13]. However, there are
some studies which have questioned the validity of these
classification systems [2,14]. Therefore, we focused our
analysis on the drugs which are documented as tera-
togenic in humans. Published studies that evaluate drug
use during pregnancy have used varying methodologies
including the collection of prescriptions [15], interview of
mothers [16], and use of pharmacy records [17]. Further-
more, the analysis of drug use in those studies has been
done based on various risk classification systems, which
makes the comparison of our results with those studies
difficult. However, the proportion of pregnant women
who were prescribed potentially teratogenic drugs (0.8%)
is comparable to the recently published results of Andrade
et al (2006), who have reported that 1.1% pregnant pop-
ulation in United States received a teratogenic drug [18].
We understand that ours is a snap shot study which has
analyzed the prescriptions issued to women during preg-
nancy. This is exactly in accordance with the objective of
the study which was to evaluate the prescribing trends of
Pakistani physicians. However, the actual exposure to
potentially teratogenic drugs could well be different. This
is especially in the context of Pakistan where most of the
pregnancies are unplanned. The pregnant women might
be taking drugs before they know that they have become
pregnant.
There are certain situations where the doctors are left with
no option but to prescribe teratogenic drugs when a suit-
able replacement is not available and/or when the bene-
fits of the drug to the mother outweigh the possible risk to
the fetus. The use of anti-epileptic drugs is one good exam-
ple in this context [19]. However, anecdotal reports sug-
gest an alarming trend in Pakistan that many doctors are
prescribing the drugs without knowing their significant
toxic effects, drug interaction and contraindications.
Based on those reports, we expected very high rate of pre-
scription of potentially teratogenic drugs. Contrary to our
expectation, this study revealed a rather careful prescrib-
ing behaviour of the physicians to pregnant women. The
percentage of women who were prescribed teratogenic
drugs was comparable to that reported in USA [18].
Another observation from the current study was the rela-
tively smaller number of women in their first trimester,
who were recruited. We tried to recruit all pregnant
women attending the clinics, but the proportion of them
in their first trimester was less in all the five sampling
units. The less number of women from first trimester in
our study is perhaps because of the fact that pregnant
women in Pakistan start seeking antenatal care in
advanced pregnancy.
It is emphasized that the results of the present study can
reasonably be considered as the prescribing trends preva-
lent in the tertiary care hospitals of the whole of Pakistan
because of the representativeness of the sampling units.
The five sampling units of the study covered four cities
and towns of two (out of four) provinces with a wide eth-
nic, socioeconomic and geographical variations. None-
theless, the results from all the hospitals were almost
similar in terms of prescribing patterns of the physicians.
Conclusion
Less than one percent of the pregnant women attending
tertiary care hospitals in Pakistan are prescribed tera-
togenic drugs. The prescribing practices of Pakistani phy-
sicians are similar to those in western countries.
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